Abacavir/Lamivudine Clonmel 600mg/300mg Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine clonmel 600mg/300mg film-coated tablets

clonmel healthcare ltd - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine mylan 600 mg/300 mg film-coated tablets

generics (uk) limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Abacavir/Lamivudine Teva 600 mg/300 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine teva 600 mg/300 mg film-coated tablets

teva b.v. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Abacavir/Lamivudine 600 mg/300 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine 600 mg/300 mg film-coated tablets

accord healthcare limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Abacavir/Lamivudine 600 mg/300 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine 600 mg/300 mg film-coated tablets

accord healthcare ireland ltd. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Genvoya European Union - English - EMA (European Medicines Agency)

genvoya

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infections - antivirals for systemic use, - genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (hiv 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.,

Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine mylan 600 mg/300 mg film-coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - abacavir; lamivudine - film-coated tablet - 600mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Abacavir/Lamivudine Mylan Pharma 600 mg/300 mg Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

abacavir/lamivudine mylan pharma 600 mg/300 mg film-coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - abacavir sulfate; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Dutrebis 150 mg film-coated tablets lamivudine, raltegravir European Union - English - myHealthbox

dutrebis 150 mg film-coated tablets lamivudine, raltegravir

merck sharp & dohme limited - lamivudine, raltegravir potassium - film-coated tablets - 150 mg of lamivudine and 300 mg of raltegravir - hiv infections - antivirals for systemic use - indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the insti (integrase strand transfer inhibitor) and nrti (nucleoside reverse transcriptase inhibitor) classes

Dutrebis European Union - English - EMA (European Medicines Agency)

dutrebis

merck sharp dohme limited - lamivudine, raltegravir potassium - hiv infections - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis is indicated in combination with other anti‑retroviral medicinal products for the treatment of human immunodeficiency virus (hiv‑1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the insti (integrase strand transfer inhibitor) and nrti (nucleoside reverse transcriptase inhibitor) classes (see sections 4.2, 4.4 and 5.1).